Workflow
麦澜德: 南京证券股份有限公司关于南京麦澜德医疗科技股份有限公司使用自筹资金支付募投项目款项后续以募集资金等额置换的核查意见

Core Viewpoint - The company, Nanjing Mairande Medical Technology Co., Ltd., is utilizing self-raised funds to pay for investment projects and will subsequently replace these with raised funds in an equivalent amount, ensuring compliance with regulations and maintaining operational efficiency [1][5][7]. Fundraising Overview - The total amount raised from the initial public offering (IPO) was RMB 90,975.85 million, with a net amount of RMB 90,975.85 million after expenses. The share price was set at RMB 40.29 [1]. - The funds are stored in a dedicated special account, and a tripartite supervision agreement has been signed with the sponsor and the commercial bank [2]. Investment Project Details - The total investment for the projects is RMB 7,622.54 million, with RMB 65,000.48 million planned to be funded from the raised funds and RMB 57,377.94 million from self-raised funds [2]. Reasons for Using Self-Raised Funds - The company needed to use self-raised funds initially due to regulatory requirements for employee salary payments and other operational expenses, which could not be processed through the special fund account [3][4]. - This approach aims to enhance the efficiency of fund usage and project implementation [6]. Replacement of Funds - As of the date of the report, the company has replaced a total of RMB 2,122.47 million of self-raised funds with raised funds, covering expenses such as salaries, utilities, and government payments [4][5]. Impact on Operations - The use of self-raised funds for project payments will not affect the normal implementation of investment projects and is designed to improve operational efficiency [6][7]. Review Procedures - The board of directors and the supervisory board have approved the use of self-raised funds and the subsequent replacement with raised funds, confirming that the process complies with relevant regulations [6][7].